USANA Health Sciences (NYSE: USNA) reported Q2 EPS of $1.00, $0.13 worse than the analyst estimate of $1.13. Revenue for the quarter came in at $264 million versus the consensus estimate of $268.44 million.

GUIDANCE:

USANA Health Sciences reiterates FY2022 EPS of $3.85-$4.45, versus the consensus of $4.42. USANA Health Sciences sees FY2022 revenue of $1.015-1.065 billion, versus the consensus of $1.06 billion.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.